OTTAWA, March 24 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP - News; "PharmaGap" or "the Company") and the Ottawa Health Research Institute ("OHRI") have entered into a testing program for PharmaGap's lead cancer drug compound, PhG-alpha-1. OHRI researchers led by Dr. Barbara Vanderhyden will study the compound in ovarian cancer cell lines in order to assess the potency of PharmaGap's drug compound as a single agent therapeutic and in combination with the current standard of care chemotherapeutic used to treat ovarian cancer.